Revenue Breakdown
Composition ()
No data
Revenue Streams
Niagen Bioscience Inc (NAGE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumer Products Segments, accounting for 76.6% of total sales, equivalent to $26.02M. Other significant revenue streams include Ingredients Segments and Analytical Reference Standards and Service segment. Understanding this composition is critical for investors evaluating how NAGE navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Niagen Bioscience Inc maintains a gross margin of 64.52%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.46%, while the net margin is 13.47%. These profitability ratios, combined with a Return on Equity (ROE) of 38.90%, provide a clear picture of how effectively NAGE converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NAGE competes directly with industry leaders such as NATR and USNA. With a market capitalization of $483.26M, it holds a leading position in the sector. When comparing efficiency, NAGE's gross margin of 64.52% stands against NATR's 73.28% and USNA's 77.15%. Such benchmarking helps identify whether Niagen Bioscience Inc is trading at a premium or discount relative to its financial performance.
